Microbiome Changes in Chronic Liver Disease Highlight the Need for Personalized Treatment Nov. 18, 2024 — People with chronic liver disease have dramatic changes to the types and functions of ...

SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company ...

Liver disease affects millions of adults in the United States, posing serious risks to health if left untreated. Among the ...

With an estimated two billion people affected worldwide, fatty liver disease is a silent epidemic that often goes unnoticed ...

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...

In 2023, the United States represented the largest portion of the Liver Fibrosis market, comprising around 79% of the total ...

Rencofilstat is under clinical development by Hepion Pharmaceuticals and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its ...

The current standard treatment involves therapeutic ... The US market of recurrent and refractory ascites due to liver cirrhosis is forecast to grow by an average of 9% per year, from approximately 70 ...

In a matter of a few months, he went from a NASH diagnosis ... including the treatment of conditions like MASLD. Given the clear connection between obesity and liver disease, it’s critical ...

This study highlights that metabolic disorders resulting from bacterial imbalance in the liver are significant contributors to the pathogenesis of NAFLD, and investigating the relationship between ...